So I kind of had, I really liked the idea about measuring the number of genomes in the blood using a scanning technology. The issue is that in a disease like myeloma, the sensitivity is going to be limited by the number of genomes that are in the blood. So my suspicion is that that's not going to work out as sensitive as mass spec. And so I actually think mass spec is going to come to dominate and be the routine kind of diagnostic approach for looking for M.R.D.

And Dr. Despens, the area of social mother advantages, which were you could distinguish the drugs, the antibody drugs from the tumor. You can distinguish the tumor clone from regenerating clones after transplant. And she didn't talk about it today, but I know that they're working on forms of the protein that are amyloid, that are amyloid, like co-sulated forms of them. So that's also going to be very interesting. So the session before that was on new drugs and for the audience, what did we learn their faith?

So we had a couple of talks in there. So we had a number of talks about image resistance and how that can make a difference. The audience or you revel in pumilloid of my... Yeah, Reverend Pumilloid of my... But they also talking about some of the newer image, CC220 and 9128. Too far, 8. Nearly there. And so that was very interesting. Had a great talk about immunogenic cell death and how important that is for many of the drugs we've been using for years, like proteosome inhibitors, but also for some of the newer drugs. And I found that particularly interesting because Ken Anderson was saying that in the high-risk patients, it may be that those cases are unable to use immunogenic cell death and that might be why they're more high risk. So that was great. We had a really nice talk from Suzanne Lynch about eutharometh therapies for amyloid and how they're using similar approaches with bispycific antibodies and also reproprogramming macophages to kind of kill off amyloid cells. So that

was good. It seems to be more and more mounting evidence that what we've always thought of as being directly cytotoxic drugs may in fact work in large part through the immune system, including the immune modulators and maybe even proteosome inhibitors, which we never really thought about

in the context of immunity.